Humacyte HUMA
NASDAQ HUMA
$0.68 -0.05 (-6.85%)
At close: Aug 20, 2026 · 4:00 PM EDT

Humacyte (HUMA) Operating Leases (2020 - 2023)

Humacyte (HUMA) posted quarterly Operating Leases of $632000.0 for Q4 2023, down 9.71% year-over-year from $700000.0 in Q4 2022, and up 1.94% quarter-over-quarter from $620000.0 in Q1 2023.

Humacyte (HUMA) Operating Leases (2020 - 2023) Analysis & Trends

Humacyte (HUMA) has reported Operating Leases for 4 consecutive years, with $632000.0 the latest figure, recorded in Q4 2023.

  • In Q4 2023, Operating Leases fell 9.71% year-over-year to $632000.0; the TTM figure through Dec 2023 stood at $632000.0 (down 9.71% YoY), while the FY2023 annual figure was $632000.0, down 9.71% from the prior year.
  • Operating Leases advanced to $632000.0 in Q4 2023 per HUMA's latest filing, from $620000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $727000.0 in Q4 2020 and bottomed at $620000.0 in Q1 2023.
  • Historically, Operating Leases has averaged $671666.7 across 4 years, with a median of $670000.0 in 2022.
  • Annual changes were most pronounced in 2022 — Operating Leases changed 0.0% — and 2023, when it decreased 9.71%.
  • Humacyte's Operating Leases stood at $727000.0 in 2020, then slipped by 3.71% to $700000.0 in 2021, then changed by 0.0% to $700000.0 in 2022, then slipped by 9.71% to $632000.0 in 2023.
  • Business Quant data shows HUMA's Operating Leases at $632000.0 in Q4 2023, $620000.0 in Q1 2023, and $700000.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn -
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn
10 Humacyte 158.12 Mn 158.12 Mn -825,000.00

Historic Data

Download Data
DateValue
Dec 31, 2023 632,000.00
Mar 31, 2023 620,000.00
Dec 31, 2022 700,000.00
Sep 30, 2022 645,000.00
Jun 30, 2022 658,000.00
Mar 31, 2022 670,000.00
Dec 31, 2021 700,000.00
Sep 30, 2021 693,000.00
Dec 31, 2020 727,000.00